Attached files

file filename
EX-99.1 - EXHIBIT 99.1 - ENDOCYTE INCv437290_ex99-1.htm





Washington, D.C. 20549





Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934


Date of Report (Date of earliest event reported) April 19, 2016


Endocyte, Inc.
(Exact name of registrant as specified in its charter)


Delaware   001-35050   35-1969-140
(State or other jurisdiction   (Commission   (IRS Employer
of incorporation)   File Number)   Identification No.)


3000 Kent Avenue, Suite A1-100

West Lafayette, Indiana 47906

(Address of principal executive offices)    (Zip Code)


Registrant's telephone number, including area code 765-463-7175


Not Applicable
(Former name or former address, if changed since last report.)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))





Item 7.01 Regulation FD Disclosure.


The information contained in this Item 7.01 shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.


On April 19, 2016, Endocyte, Inc. (the "Company") issued a press release announcing promising preclinical data for application of the Company’s small molecule drug conjugate (SMDC) technology in a chimeric antigen receptor (CAR) T cell therapy in a late-breaking abstract at the American Association for Cancer Research (AACR) Annual Meeting 2016 in New Orleans. A copy of this press release is attached to this Current Report as Exhibit 99.1 and is incorporated herein by reference.


Item 9.01 Financial Statements and Exhibits.


(d) Exhibits


Exhibit No.   Description
99.1   Press release dated April 19, 2016







Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Dated: April 19, 2016


  By: /s/ Beth A. Taylor
    Beth A. Taylor
    Corporate Controller





Exhibit Index


Exhibit No.   Description
99.1   Press Release Issued April 19, 2016